secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001193125-24-005188
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara raises $15M via pre-funded warrants; Nasdaq warns of bid price deficiency
-------------------------------------------------------------------------------

- Gross proceeds of ~$15M from sale of pre-funded warrants to purchase up to 27,272,727 shares at $0.55/warrant.
- Warrants exercisable immediately at $0.0001/share, no expiration; proceeds for working capital and R&D.
- Nasdaq notified ATRA that bid price closed below $1.00 for 30 consecutive days; 180-day cure period until July 8, 2024.
- If not cured, company may transfer to Nasdaq Capital Market or effect reverse stock split; delisting possible.
- Offering expected to close January 10, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524005188/0001193125-24-005188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524005188/d703135d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-005188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer